Bard
This article was originally published in The Gray Sheet
Executive Summary
Programmable pain pump development effort is abandoned, resulting in a Q4 write-off of $3-$6 mil. Bard has no plans to pursue any other pain management product line "at this point," Chairman and CEO Timothy Ring reported during a Jan. 28 earnings call. Revenue for 2003 totaled $1.43 bil., up 13%; net income of $168.5 mil., up 8.7%, includes a $35.5 mil. after-tax charge resulting from a brachytherapy lawsuit (1"The Gray Sheet" Jan. 5, 2004, In Brief)...